CN Patent

CN110101669A — 一种乌帕替尼颗粒的生产工艺

Assigned to Nanjing New Enzyme Pharmaceutical Technology Co Ltd · Expires 2019-08-09 · 7y expired

What this patent protects

本发明公开了一种乌帕替尼颗粒的生产工艺，涉及乌帕替尼颗粒的生产领域。该乌帕替尼颗粒的生产工艺，由乌帕替尼原料药依次经粉碎过筛、辅料混合、制粒干燥、整粒筛选、质量检测和分剂量生产制成。与现有技术相比，本发明的有益效果是：整体生产过程简洁明了，不仅有效提高了产量，还能保证成品乌帕替尼颗粒的粒径、成分以及水分含量等各项指标达标，确保了乌帕替尼颗粒的药效，并且还提高了乌帕替尼颗粒口服时的口感，提升了患者的治疗体验，具有广阔的市场前景。

USPTO Abstract

本发明公开了一种乌帕替尼颗粒的生产工艺，涉及乌帕替尼颗粒的生产领域。该乌帕替尼颗粒的生产工艺，由乌帕替尼原料药依次经粉碎过筛、辅料混合、制粒干燥、整粒筛选、质量检测和分剂量生产制成。与现有技术相比，本发明的有益效果是：整体生产过程简洁明了，不仅有效提高了产量，还能保证成品乌帕替尼颗粒的粒径、成分以及水分含量等各项指标达标，确保了乌帕替尼颗粒的药效，并且还提高了乌帕替尼颗粒口服时的口感，提升了患者的治疗体验，具有广阔的市场前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN110101669A
Jurisdiction
CN
Classification
—
Expires
2019-08-09
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing New Enzyme Pharmaceutical Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.